Ubs Group Ag Applied Molecular Transport Inc. Transaction History

Ubs Group Ag

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$0.24 - $0.37 $1,956 - $3,015	-8,150 Reduced 78.49%	2,233 $0
Q1 2023 May 12, 2023	SELL	$0.32 - $0.68 $590 - $1,253	-1,844 Reduced 15.08%	10,383 $3,000
Q4 2022 Feb 08, 2023	SELL	$0.35 - $1.26 $447,922 - $1.61 Million	-1,279,779 Reduced 99.05%	12,227 $5,000
Q3 2022 Nov 10, 2022	BUY	$1.12 - $3.12 $1.45 Million - $4.03 Million	1,292,006 New	1,292,006 $1.26 Million
Q1 2022 May 16, 2022	SELL	$5.63 - $13.88 $42,444 - $104,641	-7,539 Closed	0 $0

Q4 2021 Feb 14, 2022	SELL	$13.23 - $26.05 $449,105 - $884,293	-33,946 Reduced 81.83%	7,539 $106,000
Q3 2021 Nov 15, 2021	BUY	$25.87 - $46.61 $1.04 Million - $1.87 Million	40,136 Added 2975.24%	41,485 $1.07 Million
Q2 2021 Aug 13, 2021	SELL	$39.76 - $64.31 $156,892 - $253,767	-3,946 Reduced 74.52%	1,349 $62,000
Q1 2021 May 12, 2021	BUY	$30.5 - $74.14 $156,007 - $379,226	5,115 Added 2841.67%	5,295 $233,000
Q4 2020 Feb 11, 2021	BUY	$29.39 - $35.0 $5,290 - $6,300	180 New	180 $6,000
Q3 2020 Nov 12, 2020	SELL	$20.49 - $33.58 $18,830 - $30,860	-919 Closed	0 $0
Q2 2020 Jul 31, 2020	BUY	$17.98 - $28.0 $16,523 - $25,732	919 New	919 $23,000

9.42K

Ticker AMTI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,900,600
Description
Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral and respiratory biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of r...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.